Literature DB >> 8731722

Fibrate monotherapy and profound hypoalphalipoproteinaemia.

A O Olukoga, V E Crowley, M F Stewart, O Weinkove.   

Abstract

Mesh:

Substances:

Year:  1996        PMID: 8731722      PMCID: PMC2398406          DOI: 10.1136/pgmj.72.845.189

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  5 in total

Review 1.  Lipid lowering drugs.

Authors:  P O'Connor; J Feely; J Shepherd
Journal:  BMJ       Date:  1990-03-10

2.  Ciprofibrate and lipid profile.

Authors:  H A Chandler; A J Batchelor
Journal:  Lancet       Date:  1994-07-09       Impact factor: 79.321

3.  Lipid profiles on fibric-acid derivatives.

Authors:  N E Capps
Journal:  Lancet       Date:  1994-09-03       Impact factor: 79.321

4.  Ciprofibrate and lipid profile.

Authors:  A J McLeod; R J Warren; M Armitage
Journal:  Lancet       Date:  1994-10-01       Impact factor: 79.321

5.  Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.

Authors:  M J Murphy; A Duncan; B D Vallance; C J Packard; D S O'Reilly
Journal:  Postgrad Med J       Date:  1995-08       Impact factor: 2.401

  5 in total
  1 in total

1.  Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.

Authors:  A O Olukoga
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.